Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study

There have been very few prospective studies of first-line chemotherapy on advanced gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). This phase II study assessed the activity and safety of irinotecan plus cisplatin (IP) followed by octreotide long-acting release (LAR) maintenance treatment...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Li, Jie, Lu, Ming, Lu, Zhihao, Li, Zhongwu, Liu, Yiqiang, Yang, Li, Li, Jian, Zhang, Xiaotian, Zhou, Jun, Wang, Xicheng, Gong, Jifang, Gao, Jing, Li, Yan, Shen, Lin
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2016
Subjects:
Clinical Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5421960/
https://ncbi.nlm.nih.gov/pubmed/27788498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12900
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items